ZenBio is a global leader in providing advanced cell-based solutions and services to the biotechnology and health care industries. Established in 1995, the company's primary focus is on offering cutting-edge human primary cell culture products and services, with an emphasis on adipose-derived stem cells (ASCs). ZenBio's mission is to supply high-quality human cell systems, reagents, and contract services to research partners, commercialize innovative research tools, and accelerate discovery through research and development and strategic alliances. The company's wide range of cell systems includes adipocytes, stem cells, hepatocytes, and various other human primary cell types, with a specialization in custom cell isolations from diverse tissue types. Based in the United States, ZenBio aims to continue its legacy of pioneering advancements in cell-based solutions and services. With a strong track record of industry leadership and commitment to innovation, ZenBio is well-positioned to make a significant impact within the life science, cosmetics, and personal care communities.
There is no investment information
No recent news or press coverage available for ZenBio, A BioIVT Company.